cd22 car-t

Leukemia

Stanford UniversityCell therapyPhase 1Active

C

37/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / Sponsor	Phase	Rating
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
ASPARAGINASE Gruppo Italiano Malattie EMatologiche dell'Adulto	Phase 3	BB
THIOGUANINE ANHYDROUS Incyte Corporation	Phase 3	BB
Idarubicine Affiliated Hospital of Nantong University	Phase 3	BB
Daunorubicin Richard Stone, MD	Phase 3	BB

View all 50 →

Same molecule, other indications

cd22 car-t is also rated in:

non-Hodgkin lymphomaDormant

B

Indicative ·

57 / 100

B-cell non-Hodgkin lymphomaDormant

CCC

Indicative ·

50 / 100

B-cell Lymphoma RecurrentDormant

CCC

Indicative ·

50 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.